Structure’s oral GLP-1 a ‘work in progress’ following Phase IIa obesity and diabetes data

Kyle LaHucik

Senior Reporter

Phase IIa data for Structure Therapeutics’ oral GLP-1 drug candidate for type 2 diabetes and obesity bested analyst expectations on safety and tolerability, but lower-than-hoped-for efficacy results set it up for more work in the next round of testing in 2024.

The San Francisco biotech’s once-daily oral candidate, GSBR-1290, is being tested in people with obesity and type 2 diabetes. It plans to kick off Phase IIb trials in the second half of 2024 to try and stake its place in the fast-moving race to be the next generation of drugs after Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Structure’s oral GLP-1 a ‘work in progress’ following Phase IIa obesity and diabetes data

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Teva to close additional manufacturing sites as it enters next phase of 'pivot to growth'

Medical Affairs: The Critical Link Between Science, Physicians and Patients

Struc­ture’s oral GLP-1 a ‘work in progress’ fol­low­ing Phase IIa obe­si­ty and di­a­betes da­ta

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Af­ter eight years with Sanofi, Frank Nes­tle de­parts as CSO, glob­al head of re­search

In­side CVS Care­mark’s move that broke Hu­mi­ra’s hold on the mar­ket

'Big­ger, faster, bet­ter': Iso­mor­phic, Deep­Mind un­veil Al­phaFold 3, go­ing be­yond pro­tein pre­dic­tions

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

Te­va to close ad­di­tion­al man­u­fac­tur­ing sites as it en­ters next phase of 'piv­ot to growth'

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

Structure’s oral GLP-1 a ‘work in progress’ following Phase IIa obesity and diabetes data

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Teva to close additional manufacturing sites as it enters next phase of 'pivot to growth'

Medical Affairs: The Critical Link Between Science, Physicians and Patients